154 related articles for article (PubMed ID: 35023026)
1. Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wang X; Zhang W; Zhang M; Zhang F; Xiao J; Yin Q; Han H; Li T; Lin G; Zhuge Y
Hepatol Int; 2022 Jun; 16(3):669-679. PubMed ID: 35023026
[TBL] [Abstract][Full Text] [Related]
2. Histological evaluation of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: Correlation with Drum Tower Severity Scoring.
Li R; Li L; Cai Z; Chen J; Zhang H; Zhao S; Tu J; Sun C; Jin Y; Zhang M; Zhang F; Zhang W; Yin Q; Xu H; Han H; Li T; Zhuge Y; Xiao J
Dig Liver Dis; 2024 Jul; 56(7):1220-1228. PubMed ID: 38151450
[TBL] [Abstract][Full Text] [Related]
3. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study.
Peng C; Zhang X; Zhang F; Liu L; Shao Y; Xiang X; Zhang W; Xiao J; Wang Y; Zhang B; Yin Q; Song Y; Mo Z; Zou X; Zhang M; Zhuge Y
Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1168-1178. PubMed ID: 31834055
[TBL] [Abstract][Full Text] [Related]
5. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological analysis of 16 cases of pyrrolizidine alkaloids-associated hepatic sinusoidal obstruction syndrome].
Li YS; Bao J; Xu Y; Wang TL
Zhonghua Gan Zang Bing Za Zhi; 2020 Apr; 28(4):332-337. PubMed ID: 32403886
[No Abstract] [Full Text] [Related]
7. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease.
Zhuge YZ; Wang Y; Zhang F; Zhu CK; Zhang W; Zhang M; He Q; Yang J; He J; Chen J; Zou XP
Liver Int; 2018 Oct; 38(10):1867-1874. PubMed ID: 29297975
[TBL] [Abstract][Full Text] [Related]
8. Mid- to long-term outcomes of initial transjugular intrahepatic portosystemic shunt versus anticoagulation for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Huang Q; Zhang Q; Xu H; Zu M; Xiao J; Shen B
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):445-452. PubMed ID: 36719828
[TBL] [Abstract][Full Text] [Related]
9. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.
Lin G; Wang JY; Li N; Li M; Gao H; Ji Y; Zhang F; Wang H; Zhou Y; Ye Y; Xu HX; Zheng J
J Hepatol; 2011 Apr; 54(4):666-73. PubMed ID: 21146894
[TBL] [Abstract][Full Text] [Related]
10. Tusanqi and hepatic sinusoidal obstruction syndrome.
Wang JY; Gao H
J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.
Kan X; Ye J; Rong X; Lu Z; Li X; Wang Y; Yang L; Xu K; Song Y; Hou X
Sci Rep; 2016 Nov; 6():37998. PubMed ID: 27897243
[TBL] [Abstract][Full Text] [Related]
12. Hepatic sinusoidal obstruction syndrome caused by the ingestion of
Cen P; Ding J; Jin J
J Int Med Res; 2021 Apr; 49(4):300060520980649. PubMed ID: 33845617
[TBL] [Abstract][Full Text] [Related]
13. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.
Yang M; Ruan J; Gao H; Li N; Ma J; Xue J; Ye Y; Fu PP; Wang J; Lin G
Arch Toxicol; 2017 Dec; 91(12):3913-3925. PubMed ID: 28620673
[TBL] [Abstract][Full Text] [Related]
14. Gynura segetum induces hepatic sinusoidal obstruction syndrome in a child: A case report.
Zheng Q; Zhang H
Medicine (Baltimore); 2024 Mar; 103(11):e37341. PubMed ID: 38489699
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt.
Xiao J; Tu J; Zhang H; Zhang F; Zhang W; Xu H; Yin Q; Yang J; Han H; Wang Y; Zhang B; Peng C; Zou X; Zhang M; Zhuge Y
Hepatol Int; 2021 Jun; 15(3):720-729. PubMed ID: 33507485
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.
Liu F; Rong X; Guo H; Xu D; Liu C; Meng L; Yang X; Guo T; Kan X; Song Y
BMC Gastroenterol; 2020 Feb; 20(1):30. PubMed ID: 32019495
[TBL] [Abstract][Full Text] [Related]
17. Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid.
Tu H; Li M; Chen Z; Zhao J; Wang H; Qian J; Wei C; Yang Y; Zhu Y; Zuo L
J Clin Lab Anal; 2022 Feb; 36(2):e24240. PubMed ID: 35034375
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin attenuates pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression.
Xiang H; Liu C; Xiao Z; Du L; Wei N; Liu F; Song Y
Liver Int; 2023 Mar; 43(3):626-638. PubMed ID: 36354295
[TBL] [Abstract][Full Text] [Related]
19. [Study of PA-HSOS severity grading to predict the prognosis of patients with PA-HSOS treated by transjugular intrahepatic portosystemic shunt].
Chen YR; Zhang W; Zhang M; Zhang F; Xiao JQ; Yin Q; Zhuge YZ
Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):46-53. PubMed ID: 33541023
[No Abstract] [Full Text] [Related]
20. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
Yang XQ; Ye J; Li X; Li Q; Song YH
World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
